Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,403,907 papers from all fields of science
Search
Sign In
Create Free Account
BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I
Known as:
BCR-ABL1 T315I Mutation
, BCR-ABL Thr315Ile Mutation
, BCR/ABL Fusion Protein with T315I
Expand
A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
BCR-ABL Fusion Gene
Fusion Gene
Neoplastic Cell Transformation
Oncogenes
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
M. Massimino
,
Maria Letizia Consoli
,
+12 authors
P. Vigneri
Carcinogenesis
2014
Corpus ID: 14618004
Interferon regulatory factor 5 (IRF5) modulates the expression of genes controlling cell growth and apoptosis. Previous findings…
Expand
2014
2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
M. Agrawal
,
Benjamin Hanfstein
,
+10 authors
M. Müller
Leukemia
2014
Corpus ID: 205195944
In the face of competing tyrosine kinase inhibitors (TKIs), identification of chronic myeloid leukemia (CML) patients expecting…
Expand
2014
2014
Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells
Lili Song
,
Yaoyao Tu
,
+7 authors
Yingli Wu
PLoS ONE
2014
Corpus ID: 10864563
Despite considerable efficacy of arsenic trioxide (As2O3) in acute promyelocytic leukemia (APL) treatment, other non-APL…
Expand
2010
2010
ABL Alternative Splicing Is Quite Frequent in Normal Population - Letter
I. Santamaría
,
A. Pitiot
,
M. Balbín
Molecular Cancer Therapeutics
2010
Corpus ID: 29947129
In the article by Lee et al. (1), an alternative splicing of BCR-ABL is proposed as a mechanism for imatinib resistance in…
Expand
2007
2007
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Wanlong Ma
,
R. Tseng
,
+7 authors
M. Albitar
Haematologica
2007
Corpus ID: 39408671
BACKGROUND AND OBJECTIVES Quantitation of BCR-ABL mRNA is emerging as the standard of care to monitor the status of chronic…
Expand
Highly Cited
2005
Highly Cited
2005
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
F. Gruber
,
Trond Lamark
,
+5 authors
Bjørn Skogen
Leukemia
2005
Corpus ID: 5679537
Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in…
Expand
2005
2005
Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.
M. Mueller
,
P. Erben
,
+7 authors
A. Hochhaus
2005
Corpus ID: 89711271
Quantitative determination of residual BCR-ABL transcript levels has been accepted as integral part of the management of CML…
Expand
2000
2000
Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML
M. Dupont
,
E. Jourdan
,
J. Chiésa
Leukemia
2000
Corpus ID: 13508234
Molecular analysis of the Philadelphia (Ph) chromosome has shown that the 39 sequences of the tyrosine kinase c-ABL proto…
Expand
1998
1998
A polymorphism in exon b2 of the major breakpoint cluster region (M‐bcr) identified in chronic myeloid leukaemia patients
R. V. Meissner
,
P. Dias
,
D. Covas
,
F. Job
,
M. Leite
,
N. Nardi
British Journal of Haematology
1998
Corpus ID: 37015287
The BCR/ABL junctional region and the b3 exon from chronic myeloid leukaemia (CML) patients were sequenced. In all 21 samples…
Expand
1988
1988
Rearrangement of the Breakpoint Cluster Region and Expression of P210 BCR-ABL in a "Masked" Philadelphia Chromosome-Positive Acute Myeloid Leukemia
C. Price
,
F. Rassool
,
+5 authors
L. Wiedemann
1988
Corpus ID: 208541773
The Philadelphia (Ph) translocation t(9;22)(q34;q11) occurs frequently in chronic myeloid leukemia (CML) but is less common in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE